How These Drugs Actually Work (The Simple Version)
When you eat, your gut releases a hormone called GLP-1. This does three things: tells your pancreas to release insulin, tells your brain you're full, and slows down your stomach so food digests gradually. The problem is natural GLP-1 breaks down in seconds. It's gone before it can do much.
Semaglutide (Ozempic, Wegovy) is a lab-modified version of GLP-1 that lasts a full week instead of seconds. That's the entire innovation. One injection, and you have a week of: reduced hunger, better blood sugar control, and slower digestion. It works because it mimics what your body already does — just for longer.
But GLP-1 is just one hormone. Your body uses multiple hormones to regulate weight and metabolism. That's where the next generation comes in.
The Three Generations — And Why It Matters
Generation 1: Semaglutide (Ozempic / Wegovy) GLP-1 Only
Targets one receptor: GLP-1. This is the drug that started the revolution.
- Average weight loss: 15% of body weight over 68 weeks (STEP trials, 4,541 people)
- Heart protection: 20% reduction in heart attacks, strokes, and cardiovascular death over 4 years (SELECT trial, 17,604 people) — and this benefit was independent of weight loss
- Brain protection: Observational data shows 26% lower dementia risk in people with type 2 diabetes on semaglutide. Animal studies show it reduces the amyloid plaques that cause Alzheimer's
- Diabetes control: Reduces HbA1c (3-month blood sugar average) by 1.5-2%, which is substantial
The trade-offs: Nausea and GI upset in the first 4-8 weeks (most people). Muscle loss — up to 30-40% of weight lost can be muscle if you don't strength train. About 50% of weight returns within a year of stopping. Costs roughly £150-250/month privately in the UK.
Status: Fully approved by FDA, EMA, MHRA. Prescription required. The gold standard for safety data in this class.
Generation 2: Tirzepatide (Mounjaro / Zepbound) GLP-1 + GIP Dual
Targets two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is another gut hormone that regulates fat metabolism and insulin secretion. By activating both, you get a stronger metabolic response than GLP-1 alone.
- Average weight loss: 20-22% of body weight at the highest dose over 72 weeks (SURMOUNT trials) — significantly more than semaglutide
- Diabetes control: Reduces HbA1c by up to 2.3% — best in class
- GI side effects: Generally similar to semaglutide, though some patients report less nausea at equivalent efficacy
- Cardiovascular data: Being evaluated but not yet as mature as semaglutide's SELECT trial
Why it's better for some people: More weight loss. Better diabetes control. The dual mechanism means the drug works through two separate pathways, so if one is less responsive in you, the other compensates.
Status: FDA-approved (Mounjaro for diabetes, Zepbound for weight loss). EMA-approved. Available in the UK privately. Some NHS prescribing for diabetes.
Generation 3: Retatrutide GLP-1 + GIP + Glucagon Triple
This is the one to watch. Retatrutide targets three receptors simultaneously: GLP-1, GIP, and glucagon. The glucagon piece is the breakthrough. Glucagon tells your liver to burn fat for energy. It also increases your metabolic rate. Adding glucagon to the mix means your body isn't just eating less — it's actively burning stored fat more aggressively.
- Phase 2 weight loss: Up to 24.2% at 48 weeks — better than semaglutide at the same timepoint
- Phase 3 weight loss (TRIUMPH-4, December 2025): Up to 28.7% weight loss at 68 weeks — an average of 71.2 lbs lost. This is approaching bariatric surgery territory without the surgery
- Liver fat: Over 90% of participants with fatty liver disease achieved normal liver fat levels. This is extraordinary — no other drug does this consistently
- Blood pressure: Reduced systolic blood pressure by 14 mmHg at the highest dose — better than most blood pressure medications
- Cardiovascular markers: Significant reductions in non-HDL cholesterol, triglycerides, and the inflammatory marker hsCRP
- Osteoarthritis: Significant pain reduction and improved physical function — likely due to combined weight loss and reduced inflammation
Why the triple agonist matters: Semaglutide suppresses appetite. Tirzepatide suppresses appetite and improves fat metabolism. Retatrutide does both AND tells your liver to actively burn fat. It's the most comprehensive metabolic intervention we've seen in a pill or injection.
What we don't know yet: Long-term safety beyond 68 weeks. Whether muscle preservation is better or worse than GLP-1 alone. Full cardiovascular outcomes data (trials ongoing). Whether the liver fat benefits persist long-term. Seven more Phase 3 readouts are expected through 2026.
Status: Investigational. Expected FDA approval around 2027. Developed by Eli Lilly. Not available for prescription yet. Multiple Phase 3 trials ongoing across obesity, diabetes, fatty liver disease, sleep apnoea, chronic back pain, and cardiovascular outcomes.
Other Compounds In The Pipeline
Survodutide (Boehringer Ingelheim) — a dual GLP-1 and glucagon agonist (no GIP). Phase 2 showed 14.9% weight loss at 46 weeks and remarkable liver fat reduction. Phase 3 trials (SYNCHRONIZE-1 and -2) are underway. Interesting because it takes a slightly different angle: glucagon plus GLP-1 without GIP, which may have different metabolic effects on the liver.
Amycretin (Novo Nordisk) — a novel dual GLP-1 and amylin receptor agonist. Phase 1b/2a data published in The Lancet (2025) showed 24.3% weight loss at the highest dose at just 36 weeks. Amylin is a hormone your pancreas releases with insulin that slows digestion and reduces appetite through a different brain pathway than GLP-1. This is Novo Nordisk's next-generation play after semaglutide.
Oral versions: Both Novo Nordisk and Lilly are developing oral GLP-1 agonists that you swallow instead of inject. Early data suggests comparable efficacy to injections. If these work, the accessibility changes completely — no more needles.
The Muscle Loss Problem — And How To Solve It
This applies to every drug in this class. When you lose weight rapidly, your body loses both fat and muscle. With GLP-1 drugs, studies suggest 25-30% of weight lost is muscle, compared to 20-25% with normal dieting. In older adults or people with limited muscle reserves, this is a genuine concern — muscle loss affects mobility, metabolic health, bone density, and independence.
The solution is resistance training. In every study where participants lifted weights while on GLP-1 drugs, muscle loss was minimal and fat loss was maximised. This isn't optional — it should be considered part of the treatment protocol. If someone prescribes semaglutide without discussing strength training, they're giving you half the picture.
What Happens When You Stop
These drugs manage the current state. They don't cure obesity. When you stop:
- Appetite returns to baseline within weeks
- About 50% of weight loss returns within the first year off medication
- Blood sugar control reverts if lifestyle hasn't changed
- The cardiovascular benefits likely diminish over time without the drug
The smart approach: use the drug as a bridge. While your appetite is suppressed, build the habits — consistent exercise, better nutrition patterns, improved sleep. Then, if you stop the medication, you have a behavioural foundation. The drug gives you a window of reduced hunger to install the habits that maintain results.
The Addiction Angle — Emerging But Real
GLP-1 receptors exist in your brain's reward centres. Patients on semaglutide are reporting reduced cravings for alcohol, nicotine, and even compulsive shopping. Animal studies confirm that GLP-1 drugs reduce reward-seeking behaviour. Clinical trials for alcohol use disorder are now underway. This could be the most unexpected benefit of this drug class — not just weight loss, but a broader reduction in compulsive behaviours. Early days, but the mechanism makes biological sense.
Neuroprotection — The Sleeper Benefit
If the dementia data holds up, GLP-1 drugs could become the most important class of drugs in modern medicine. Observational studies show semaglutide users with type 2 diabetes have 26% lower dementia risk. Animal models show GLP-1 drugs reduce the brain plaques that cause Alzheimer's, reduce neuroinflammation, and improve cerebral blood flow. Dedicated human trials are underway. If these confirm the observational data, we're looking at a drug that treats obesity, protects the heart, and prevents cognitive decline. That's an extraordinarily rare combination.
Dosing and Practical Use
Semaglutide: Start 0.25 mg weekly, titrate up to 2.4 mg weekly over 4-5 weeks. Injected subcutaneously once weekly. For diabetes: 0.5-1 mg weekly is typical.
Tirzepatide: Start 2.5 mg weekly, titrate up to 15 mg weekly. Once-weekly subcutaneous injection.
Retatrutide: Not yet available. Phase 3 doses are 8 mg and 12 mg weekly.
Side effects across all: Nausea and GI upset (first 4-8 weeks, usually resolves). Constipation. Reduced appetite (this is the mechanism, not a side effect). Rare: pancreatitis, gallstones. Very rare: thyroid concerns (seen in animal studies at unrealistic doses, not confirmed in humans).
The Honest Summary
Semaglutide is proven, approved, and works. 15% weight loss plus heart and potentially brain protection. It's the safe bet with the most safety data.
Tirzepatide is the current best-in-class. 20-22% weight loss. Approved. Better diabetes control. If semaglutide is good, tirzepatide is better for most people.
Retatrutide is the future. 29% weight loss in Phase 3. Extraordinary liver fat reduction. Approaching surgical results without surgery. Expected approval around 2027. If you can wait, this may be worth waiting for.
None of them are magic. All require resistance training to preserve muscle. All see weight regain when stopped without behaviour change. All have GI side effects. But the evidence is strong, the regulatory oversight is real, and the benefits go far beyond weight loss.
GLP-1 drugs are the beginning of a new era in metabolic medicine. The triple agonists are the next chapter. And there's more coming after that.
Considering GLP-1 Therapy?
Understanding which generation is right for you, how to dose it, how to train alongside it, and how to build habits that last after you stop — that's what makes the difference between temporary weight loss and lasting change. Let's talk about what makes sense for your situation.
Request a consultation